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sMAC (n¼50) and RTC (n¼17). HSC source was peripheral
blood (PB) (n¼30), cord (n¼14) and bone marrow (n¼6) in
sMAC group compared to all PBSC in the RTC group. 64/67
patients engrafted with no graft failure in the RTC group. The
mean time to neutrophil engraftment was comparable in the
both groups (18.0 and 18.4 days). The time to platelet count
of>20K and>50K was signiﬁcantly shorter in the RTC group
compared to sMAC group (17 and 18days compared with 32
and 40 days respectively). OS, EFS, relapse rates, were
comparable with no signiﬁcant difference in 100 day
mortality. There was no signiﬁcant difference in the rates of
>Gr 2 aGVHD (18% sMAC and 23% RTC P ¼ .7) or cGVHD
between the two groups (36% sMAC versus 47% RTC P¼ .5). A
comparison of long term toxicity including thyroid function,
growth and cardiac function showed no signiﬁcant differ-
ence at 1 and 2yrs post HSCT. However analysis of PFT (FEV1,
FEV1/FVC ratio and VC) in 25 sMAC and 7 RTC patients
showed a signiﬁcant worsening at 2 years post HSCT in the
sMAC group versus the RTC group. (P ¼ .008, 0.04 and 0.02
respectively)
Conclusions: RTC is an effective, safe conditioning regimen
with comparable outcomes to standard regimens with
a deﬁnite improvement in platelet recovery and decreased
long term pulmonary toxicity. Larger studies are needed to
modify the RTC protocol to further minimize toxicities and
improve overall QoL of survivors.265
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Background: Hematopoietic stem cell transplantation
(HSCT) outcomes continue to improve, but there remains
signiﬁcant morbidity and mortality associated with this
therapy. Acute kidney injury (AKI) has been shown to be an
independent predictor of poor outcomes in many patient
populations. Previous studies have demonstrated that
development of AKI is associated with chronic renal disease
and mortality in patients undergoing HSCT. We sought to
determine the incidence of AKI in pediatric patients during
the ﬁrst 7 and 30 days following HSCT, and to examine the
association between the presence of AKI and 100 day and 1
year survival.
Patients and Methods:We retrospectively reviewed data on
132 consecutive pediatric patients who received HSCT at
Children's Hospital of Alabama between 2000-2007. Autol-
ogous transplants were performed in 45 (34%) patients, and
allogeneic transplants were from a matched related (19%) or
unrelated (47%) donor source. Stem cell source was bone
marrow (42%), peripheral blood (36%), or umbilical cord
blood (22%). Patients were classiﬁed as having AKI if they had
either an increase in serum creatinine (SCr) 0.3 mg/dl from
the baseline value over 7 days or  150% increase in SCr, in
accordance with contemporary AKI deﬁnitions. Baseline SCr
values for all patients were obtained during the pre-trans-
plant evaluation. The incidence of AKI was determined at 7and 30 days post-transplant. Measured outcomes were
survival at day 100 and 1 year following HSCT.
Results: During the ﬁrst 100 days following HSCT, 70 of 132
(53%) of patients met criteria for AKI. Donor source did not
appear to inﬂuence the incidence of AKI; however patients
receiving bone marrow stem cells had a higher incidence of
AKI compared to other stem cell sources. 23 of 70 patients
(33%) were diagnosed with AKI during the ﬁrst week post-
HSCT, with the remainder of patients meeting criteria within
2-4 weeks post-HSCT. Of those patients that developed AKI
by 7 days post-HSCT, three of 23 patients (13%) died before
100 days following transplant and ﬁve of 23 (22%) died prior
to 1 year post-transplant, which was not signiﬁcant when
compared to those patients without AKI. In comparison, for
patients diagnosed with AKI by day 30, 14 of 70 patients
(20%) died before 100 days following transplant, and 25 of 70
patients (35%) died prior to 1 year post-transplant. Statistical
analysis revealed that presence of AKI at 30 days post-HSCT
was associated with increased mortality at 100 days post-
transplant (P ¼ .05), but not 1-year mortality.
Conclusions: This retrospective cohort study demonstrates
that AKI is a commonmorbidity following HSCT for pediatric
patients. Furthermore, we have shown that later develop-
ment of AKI (by day 30) is associated with increased day 100
mortality. Future studies are planned to determine potential
interventions to prevent or treat AKI, which could improve
outcomes for this at-risk population.266
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Although early outcomes for sickle cell disease (SCD) after
HCT have been well-reported, comprehensive long-term
outcomes is limited. We report the ﬁrst prospective long-
term follow up of pediatric patients that have undergone an
HLA-identical sibling HCT for SCD at St. Jude. The median age
for the 14 patients (11 SS, 2 SC and 1 Sb0) was 11.03.9 yrs.
Patients received BU(500 mg/m2), CY(200 mg/kg), ATG (20
mg/kg) with CSA/MTX for GVHD prophylaxis. The median
follow-up was 9.02.3 yrs. with OS of 93%, TRM of 7% and
recurrence/graft failure of 0%. Median time to engraftment
was 165 days. Incidence for acute and chronic GVHD was
34% and 21%, respectively. Hematologic parameters signiﬁ-
cantly improved after HCT (Hgb 7.51.0 to 14.11.5g/dl; HCT
25.54.7% to 42.25.0%). Indices of hemolysis signiﬁcantly
improved after HCT (retic. 0.190.20 to 0.060.12; bili.
3.04.6 to 0.40.3 mg/dl; LDH 1103583 to 16245 u/L;
ferritin 17221068 to 122613). MRI/MRA conﬁrm previous
ﬁnding that parenchymal changes continued despite normal
erythropoiesis but stabilized 5 yrs. after HCT. Abnormal TCD
velocities normalized after HCT (16639 to 8922).
Comprehensive neuropsychiatric evaluations conﬁrm stable
cognitive function after HCT with no signiﬁcant decrease in
IQ (Full: 9418 to 87 20; performance: 10416 to 8319;
verbal 8619 to 8712). Unexpectedly, 2 patients with no/
low splenic function prior to HCT had evidence of splenic
regeneration after HCT. Moreover, hepatomegaly resolved in
all patients after HCT. Renal and cardiac function was stable
with no signiﬁcant decline in CrCl or SF. Patients did not have
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on ECHO. PFTs showed stable spirometry but DLCO declined
after HCT (996 to 776, p¼0.02). Endocrine studies showed
high risk for gonadal dysfunction. Of males, 55% had normal
function, 33% were at high risk for hypogonadism and 11%
developed hypogonadism requiring therapy. Of females, 50%
had normal function and 50% developed ovarian failure
requiring therapy. Growth was monitored using bone age,
growth velocity and IGF-1. Patients with delayed growth
(35%) were able to normalized growth by 3 yrs. after HCT if
they did not have GVHD. Patients with GVHD had signiﬁcant
risk for continued delays. Bone density and DEXA scans
showed no signiﬁcant improvement in bone density and/or Z
score for whole body or lumbar spine after HCT. Risk for
osteoporosis or AVN were not decreased after HCT. In
summary, we show children with SCD with durable engraft-
ment after HCT are protected from sickle-related pathophys-
iologywith stabilization of renal, pulmonary, cardiac and CNS
dysfunction. Patients continue to be at risk for lung, bone and
gonadal damage due to HCT. To better understand the risks
associated with curative HCT we report one of the most
comprehensive systematic prospective long-term follow up
of pediatric patients that have undergone HCT for SCD.267
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Introduction: Systemic loxoscelism is a rare complication
from Loxosceles reclusa (brown recluse spider) envenomation
that occurs in children more often than adults. It is often difﬁ-
cult to diagnose and there is currently no standard treatment.
Symptoms can consist of localized skin necrosis, organ
dysfunction, hemolysis, systemic inﬂammation, and possible
death.Wepresentacaseof systemic loxoscelismthatpresented
with renal failure, hepatotoxicity, DIC, hemolytic anemia, and
secondary hemophagocytic lymphohistiocytosis (HLH).
Case Report: Our patient is a previously healthy 10 year old
male, who developed the acute onset of malaise, nausea,
fever, and a right elbow rash while attending camp in Ten-
nessee. Upon presentation to our emergency department
one day after the initiation of symptoms, he was noted to
have severe renal dysfunction, liver dysfunction, hemolytic
anemia, and thrombocytopenia. His physical exam was
signiﬁcant for fever and small, non-purulent blisters with
surrounding erythema in the right antecubital fossa. Further
investigation revealed elevation of soluble IL-2 receptor
(9204 units/ml), ferritin (>40,000 ng/ml), and triglycerides
(762 mg/dl) with hypoﬁbrinogenemia (102 mg/dl). A bone
marrow aspirate had moderate hemophagocytic activity
present. With continued worsening of his organ dysfunction,
hewas started on high dose dexamethasone therapy for HLH.
After initiation of steroid therapy, his organ dysfunction
resolved rapidly and hewas able to come off dialysis. His liver
dysfunction also resolved and his inﬂammatory markers
normalized. Investigation of his HLH did not reveal any
known disease causing mutations.
Discussion: The clinical course following brown recluse
spider bite can be relatively benign to life threatening with
severe organ dysfunction and systemic inﬂammation. Lox-
osceles venom contains pro-inﬂammatory proteins which
stimulate the production of interleukin-8, monocyte che-
moattractant protein-1, and granulocyte-macrophage
colony-stimulating factor all of which have been shown to beelevated in patients with HLH. Secondary HLH can be seen in
patients without an underlying genetic cause of the disease
and is often triggered by a concurrent medical condition.
Loxosceles envenomation should be considered as a potential
cause of secondary HLH.268
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The role of reduced intensity conditioning regimen and
impact of prior consolidation therapy with such regimens for
young adults with AML in CR1 remains controversial. At our
center from July 2005 to April 2012 we have done 52 allo-
geneic stem cell transplants for patients with acute myeloid
leukemia in CR1 using awell reported RIC regimen consisting
of Fludarabine andMelphalan. Majority of the donors (94.2%)
were HLA identical related donors. All patients received
a peripheral blood stem cell graft with a median CD34 cell
dose of 11x106/Kg. GVHD prophylaxis consisted of cyclo-
sporine combined with short course methotrexate. The
median age of the patients was 34 years (range: 11-63) and
there were 34 (65%) males. Majority (73%) were intermediate
risk patients. One patient died prior to engraftment while all
other cases engrafted with a median time to ANC>500/mm3
of 14 days and platelet count >20,000/mm3 was 16 days. 19
(36%) received an allogeneic SCT without any consolidation
therapy while the rest had consolidation therapy consisting
of either high dose cytarabine or cytarabine with an
anthracycline given for one, two or three cycles prior to
transplant. Repeated cycles of consolidation chemotherapy
were given in some cases mainly due to lack of a transplant
slots in the program, with intention to buy time prior to the
intended transplant. The treatment related mortality at 100
days was 3(5.7%) and at one year was 11(21%). Acute GVHD
grade II-IV was seen in 20(38%) and was grade III-IV in
10(19%). Chronic GVHD was seen in 29(55%) which was
extensive in 8(27%). Deaths attributable to GVHD (GVHD or
infection resulting from treatment of GVHD) occurred in 11
(21%). The 3 year KM-estimate of OS and EFS was 66.47.4%
and 61.97.5% respectively. Comparison of patients who did
not receive any consolidation therapy prior to transplant
(n¼19) versus those that received one or more consolidation
courses revealed that there was a signiﬁcantly improved OS
and a trend to improved EFS among those that received some
consolidation therapy (46.312.7% Vs.79.97.5% and
46.312.7% Vs. 71.78.7%; P-value ¼ 0.049 and 0.114
respectively). This data compared favorably with our
historical controls that received a conventional myeloa-
blative conditioning regimen (100 day and one year TRM ¼
16 % and 51% respectively). The OS and EFS was also signiﬁ-
cantly superior with the RIC conditioning regimen compared
to our myeloablative historical controls.
In conclusion allogeneic SCT with RIC regimens for young
adults with AML in CR1 results in clinical outcomes compa-
rable with those achieved by myeloablative regimens.
However, it would appear that some consolidation therapy
prior to RIC SCT is likely to improve the clinical outcome. The
optimal number and intensity of consolidation therapy
needs to be evaluated further in larger and prospective
clinical trials.
